13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001993440
Total reported value
$934.7M
$934.7M
33 檔
27.5%
At the close of Q1 2026, First Turn Management, LLC disclosed equity holdings valued at approximately $934.7M, spread across 33 reported holdings.
In Q1 2026, First Turn Management, LLC displayed an active expansion posture, initiating 5 new positions and adding to 17 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 6.94% | -2.02% | +64.72% | |
| 2 | ABVX | Abivax Sa-adr | Stock-Other | 5.80% | +1.18% | +22.20% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.77% | -0.72% | +16.83% | |
| 4 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.11% | -1.23% | -1.61% | |
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.09% | +3.23% | -26.63% | |
| 6 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.83% | -2.86% | +8.20% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 4.54% | -1.53% | -5.99% | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 4.24% | -3.89% | +0.45% | |
| 9 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.13% | -1.40% | -16.84% | |
| 10 | COGT | Cogent Biosciences Inc | Stock-Other | 4.07% | -1.58% | +14.93% | |
| 11 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 3.68% | +1.36% | +0.28% | |
| 12 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.56% | +2.16% | -8.77% | |
| 13 | IDYA | Ideaya Biosciences Inc | Stock-Other | 3.25% | -3.25% | EXIT | |
| 14 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.86% | -0.52% | +0.35% | |
| 15 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.73% | +2.45% | — | |
| 16 | CELC | Celcuity Inc | Stock-Other | 2.69% | +0.99% | — | |
| 17 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.45% | -0.85% | -2.90% | |
| 18 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.37% | -1.11% | +23.36% | |
| 19 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.09% | +2.72% | -12.89% | |
| 20 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.07% | +0.91% | — | |
| 21 | PVLA | Palvella Therapeutics Inc | Stock-Other | 2.06% | +0.50% | — | |
| 22 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.00% | +0.11% | -37.51% | |
| 23 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.99% | +1.29% | +31.98% | |
| 24 | ASND | Ascendis Pharma A/S | Stock-Other | 1.95% | -1.95% | EXIT | |
| 25 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.93% | -1.93% | EXIT | |
| 26 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.92% | -1.92% | EXIT | |
| 27 | VERA | Vera Therapeutics Inc | Stock-Other | 1.90% | -1.90% | EXIT | |
| 28 | NTRA | Natera Inc | Stock-Healthcare | 1.81% | -1.81% | EXIT | |
| 29 | ERAS | Erasca Inc | Stock-Other | 1.57% | +0.82% | — | |
| 30 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.53% | +1.46% | +18.72% | |
| 31 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.28% | -1.28% | EXIT | |
| 32 | QURE | uniQure N.V. | Stock-Other | 1.12% | +1.88% | +91.35% | |
| 33 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.66% | -0.66% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | +3.4% | +64.72% | Add |
| 2 | XENE | Xenon Pharmaceuticals Inc | +1% | -1.61% | Trim |
| 3 | ORIC | Oric Pharmaceuticals Inc | +1% | +0.35% | Add |
| 4 | ROIV | Roivant Sciences Ltd. | +0.7% | +0.28% | Add |
| 5 | APGE | Apogee Therapeutics Inc | +0.7% | +8.20% | Add |
| 6 | COGT | Cogent Biosciences Inc | +0.7% | +14.93% | Add |
| 7 | BBIO | Bridgebio Pharma Inc | +0.6% | +16.83% | Add |
| 8 | KYMR | Kymera Therapeutics Inc | +0.5% | +23.36% | Add |
| 9 | IDYA | Ideaya Biosciences Inc | +0.4% | +20.75% | Add |
| 10 | PRAX | Praxis Precision Medicines I | +0.3% | +18.72% | Add |
| 11 | MLTX | Moonlake Immunotherapeutics | +0.3% | +20.15% | Add |
| 12 | QURE | uniQure N.V. | +0.2% | +91.35% | Add |
| 13 | SRRK | Scholar Rock Holding CORP | +0.1% | -2.90% | Trim |
| 14 | NUVL | Nuvalent Inc-a | — | +0.45% | Add |
| 15 | ABVX | Abivax Sa-adr | -0.1% | +22.20% | Add |
| 16 | MIRM | Mirum Pharmaceuticals Inc | -0.2% | -16.84% | Trim |
| 17 | CYTK | Cytokinetics Inc | -0.3% | -12.89% | Trim |
| 18 | NTRA | Natera Inc | -0.3% | +0.25% | Add |
| 19 | VRDN | Viridian Therapeutics Inc | -0.5% | +31.98% | Add |
| 20 | OLMA | Olema Pharmaceuticals Inc | -0.5% | +24.44% | Add |
| 21 | FULC | Fulcrum Therapeutics Inc | -0.5% | +19.20% | Add |
| 22 | INSM | Insmed Inc | -0.7% | -5.99% | Trim |
| 23 | RVMD | Revolution Medicines Inc | -0.7% | -26.63% | Trim |
| 24 | AXSM | Axsome Therapeutics Inc | -0.8% | -8.77% | Trim |
| 25 | ASND | Ascendis Pharma A/S | -1.3% | -42.11% | Trim |
| 26 | VERA | Vera Therapeutics Inc | -1.6% | -29.87% | Trim |
| 27 | NAMS | NewAmsterdam Pharma Company N.V. | -1.6% | -37.51% | Trim |
| 28 | 430 | Terns Pharmaceuticals Inc | -2.1% | -62.54% | Trim |
| 29 | GH | Guardant Health Inc | — | EXIT | Sold out |
| 30 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 31 | CELC | Celcuity Inc | — | NEW | New buy |
| 32 | ARGX | Argenx Se - Adr | — | EXIT | Sold out |
| 33 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 34 | PVLA | Palvella Therapeutics Inc | — | NEW | New buy |
| 35 | RYTM | Rhythm Pharmaceuticals Inc | — | EXIT | Sold out |
| 36 | ERAS | Erasca Inc | — | NEW | New buy |
| 37 | RCUS | Arcus Biosciences Inc | — | EXIT | Sold out |
| 38 | IRON | Disc Medicine Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, First Turn Management, LLC reported a total U.S. public equity portfolio value of $934.7M across 33 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, ABVX, BBIO) accounted for 27.5% of total reported equity market value during Q1 2026.
Top New Position Initiated
ELVN
市值: $24.5M
Top Position Liquidated / Trimmed
GH
前期市值: $27.7M
During Q1 2026, First Turn Management, LLC's top holdings by market value included UTHR (6.9%)、ABVX (5.8%)、BBIO (5.8%). The largest single position, UTHR, represented 6.9% of total portfolio value.
In Q1 2026, First Turn Management, LLC made 38 total portfolio adjustments, initiating 5 new buys, adding to 17 positions, trimming 11 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.